Hans‐Walter Lindemann

Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial

Karolin Behringer, Helen Goergen, Felicitas Hitz et al. · The Lancet · 2014 · 181 citations

Medicine, Oncology, Pharmacology +14

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F. Barrington, David Belada et al. · The Lancet Oncology · 2018 · 159 citations · Full text

Medicine, Immunology, Oncology +13

Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial

Michael Lübbert, Olga Grishina, Claudia Schmoor et al. · Journal of Clinical Oncology · 2019 · 104 citations

Medicine, Oncology, Pharmacology +11

Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial

Hartmut Goldschmidt, K. Elias, Jan Dürig et al. · Leukemia · 2020 · 66 citations

Medicine, Hematology, Oncology +9

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

Marc‐Andrea Baertsch, K. Elias, Thomas Hielscher et al. · Blood Cancer Journal · 2021 · 33 citations · Full text

Medicine, Hematology, Pharmacotherapy +15